The accuracy, sensitivity, specificity and reproducibility of test methods have not been established and documented.
Inspection Record
Glenmark Pharmaceuticals Inc USA — FDA 483 Findings
Inspectors Adam R Cooke · Steven A Brettler · Justin A BoydThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
The quality control unit lacks authority to fully investigate errors that have occurred.
Employees engaged in the manufacture and processing of a drug product lack the training required to perform their assigned functions.
Written production and process control procedures are not followed in the execution ofproduction and process control functions and documented at the time of performance.
Laboratory records do not include complete data derived from all tests, examinations and assay necessary to assure compliance with established specifications and standards.
Routine calibration of equipment is not performed according to a written program designed to assure proper performance.
An adequate number of batches of each drug product are not tested nor are records of such data maintained to determine an appropriate expiration date.
Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
Drug product production and control records, are not reviewed and approved by the quality control unit to determine compliance with all established, approved written procedures before a batch is released or distributed.
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- Guangxi Yulin Pharmaceutical Group Co. Ltd.2025-03-21 · US FDASimilar to finding 4 Written production and process control procedures are not followed in the execution of production and process control functions and documented at the time of…
- Phoenix Innovative Healthcare Manufactures Private Limited2024-09-27 · US FDASimilar to finding 11 There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications…
- Huangshi Hygenic Material Medicine Co.2024-08-30 · US FDASimilar to finding 7 An adequate number of batches of each drug product are not tested nor are records of such data maintained to determine an appropriate expiration date.
- Tripak Pharmaceuticals Pty Ltd.2025-07-25 · US FDASimilar to finding 8 Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.
- Hybrid Pharma LLC2026-08-27 · US FDASimilar to finding 1 The accuracy, sensitivity, specificity and reproducibility of test methods have not been established and documented.
A record as of the US FDA document published on 2026-11-13. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.